aTyr Pharma (LIFE) PT Lowered to $16 at RBC Capital

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. WDC
3. DECK
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. FIX

Go back to aTyr Pharma (LIFE) PT Lowered to $16 at RBC Capital

aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

March 14, 2024 4:00 PM EDT

Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment in the second quarter of 2024.

Company launches Individual Patient Expanded Access Program (EAP), allowing access to efzofitimod for patients who complete EFZO-FIT.

Phase 2 EFZO-CONNECT study of efzofitimod in SSc-ILD currently enrolling.

Ended 2023 with $101.7 million in cash, cash equivalents and investments.

Company to host conference call and webcast today, March 14th, at 5:00 p.m. EDT / 2:00 p.m. PDT.

SAN DIEGO, March 14,... More